Kornimate/medical-research-clean huggingface dataset:
pancreatic radiofrequency under high echo-endoscopy in the management of pancreatic neuroendocrine tumors

Conditions: Neuroendocrine Tumor of Pancreas (Disorder); Neuroendocrine Tumor Grade 1

Summary: pancreatic radiofrequency ablation (rfa) could therefore be an alternative to the monitoring of pancreatic neuroendocrine tumors (pnets) and more particularly nonfunctioning pnets (nf-pnets), which is costly and anxiety-inducing for patients. to date, only a few small studies have evaluated this treatment and the results are encouraging. it appears necessary to consider a large-scale study to ensure the efficacy and low morbidity of pancreatic rfa applied to pnets.

the primary objective of the study is to evaluate the efficacy of radiofrequency treatment of grade 1 nf-pnets with a size less than or equal to 2cm. patients meeting the selection criteria will be included in the study after signing the consent. they will benefit from a rfa treatment consisting of 1 to 3 sessions depending on their response to the treatment. patients will then be followed for 5 years in order to evaluate their response to treatment, their clinical evolution, their quality of life and any complications.

Eligibility criteria:
inclusion criteria: * pancreatic mass of less than 2cm on mri, or ct scan if contraindicated by mri; * diagnosis of neuroendocrine tumor on biopsy under high echo-endoscopy (hee) with ki67\<3%, * non-secretory lesion. * homogeneous hee contrast taking; * no positron emission tomography (pet) fdg binding to the pancreatic mass; * lesion \<20mm on conventional imaging at 6 months monitoring; * age 18 to 80 years inclusive; * patient in good general condition, world health organization \[0-1\]; * signed consent to participate; * affiliation to healthcare insurance system or beneficiary of this regimen. exclusion criteria: * pregnant or likely to become pregnant (without effective contraception) or breastfeeding ; * a person in an emergency situation or deprived of liberty or placed under the authority of a tutor. * life expectancy \< 1 year; * severe hemostasis disorders; * pancreatic and/or biliary ductal dilation; * lesion considered to be adjacent to the pancreatic duct and/or bile duct; * node extension and/or metastatic disease; * patient being managed for another malignant lesion which is progressive or under treatment.

Keywords: radio frequency treatment echoendoscopy ablation efficacy
identifying residential hazards using home test kits

Conditions: Poisoning, Lead

Summary: the purpose of this project is to help families and communities identify and reduce health risks from lead, pesticides and, ultimately, other environmental hazards. we have partnered with the better housing league and baby's milk fund in cincinnati and nationally with the alliance to end childhood lead poisoning and the national center for lead safe housing. the first specific aim of this project is to evaluate a sampling kit for families to assess levels of lead and pesticides in their home environment. this aim will strengthen right-to-know laws by providing families with tools to assess environmental contamination in their own homes. the second aim is to increase community awareness of the role of environmental agents in developmental disorders, hearing loss and school problems.

a cross-sectional random, stratified study design will be used for this project. all children who are younger than 5 years of age and have a venipuncture blood sample taken at the babies milk fund clinic will be eligible for this study. after checking the lists for errors and duplications, we will randomly permute the sampling frame, stratifying on children's blood lead concentration. stratification will be used to enroll about 33% of the sample with blood lead concentrations below 5 mg/dl, 33% between 5 to 10 mg/dl, and 33% of 10 mg/dl or higher. stratifying the sample will improve our chances of testing the predictive validity of home sampling kits to identify children who have blood lead concentration \> 10 mg/dl collected by families. in addition this study will: 1. develop a pesticide wipe sampling kit to accompany our lead-sampling kit. 2. evaluate the predictive validity of home sampling kits for lead-contaminated floor dust to identify children who have blood lead levels of 10 mg/dl or higher by community participants compared with repeat samples taken by trained, community workers. 3. evaluate the reliability of home sampling kits for pesticides in dust collected by community participants compared with trained, community workers. 4. disseminate data on the reliability of home sampling tests and provide tools for families to collect environmental samples for large, population-based studies. 5. develop a healthy homes resource center at the better housing league to disseminate information to the community about residential hazards.

Eligibility criteria:
inclusion criteria: venous blood lead in residence 3 months child less than 5 years of age sampler greater than 18 years of age exclusion criteria: cannot read or understand english physically unable to conduct field sampling outside of thegreater cincinnati area

Keywords: blood lead pesticides community-based sampling kits
failure time methods for family disease studies

Conditions: Heart Diseases; Cardiovascular Diseases; Coronary Disease

Summary: to develop statistical methodologies to study genetic and environmental factors in cardiovascular disease, using age at onset data from population-based family studies of disease incidence.

background: in the study of chronic diseases, both environmental and genetic factors can be influential. in highly common diseases, such as coronary heart disease, genetic effects may be more influential in determining the age of onset of the disease than in determining whether or not one gets the disease. when sufficient information is available, family studies can help localize possible disease genes on the human chromosome through genetic linkage analysis, and familial aggregation of disease can help separate the effects of inheritance, environment and lifestyle on the risk of disease. design narrative: the study developed: (1) a general strategy for evaluating the fit of parametric dependence models for familial clustering of ages at disease-onset; (2) a computationally simple method for genetic linkage analysis of age at onset data; (3) application and illustration of recently developed additive frailty models for complex familial dependence structures. method (1) was applied to a family study of cardiovascular disease and a twin study of appendectomy. method (2) was applied to ongoing genetic studies conducted at the university of california at san francisco. method (3) was applied to a family study of coronary heart disease in western australia. well-documented, user-friendly programs were developed and made publicly available. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
fenoldopam for prevention of acute kidney injury

Conditions: Coronary Artery Disease

Summary: patients with acute coronary syndromes (acs) are at increased risk for acute kidney injury (aki) when they undergo urgent/emergency coronary angiography. the optimal medical treatment for preventing the occurrence of contrast induced - acute kidney injury is still controversial. fenoldopam mesylate is a dopamine a1 receptor agonist that augments renal plasma flow that has reduced the risk of radiocontrast dye nephropathy in some (but not all) preliminary studies. neutrophil gelatinase-associated lipocalin (ngal) is a new biomarker predictive for aki already shown to be useful for earlier diagnosis of contrast induced nephropathy. the primary objective of this study is to to test the hypothesis that fenoldopam, in addition to standard treatment, reduce the occurrence of contrast induced - acute kidney injury in patients with acute coronary syndrome (acs) undergoing urgent/emergency coronary angiography and/or percutaneous coronary intervention.

patients with acute coronary syndromes (acs) are at increased risk for acute kidney injury (aki) when they undergo urgent/emergency coronary angiography. the optimal medical treatment for preventing the occurrence of contrast induced - acute kidney injury is still controversial. fenoldopam mesylate is a dopamine a1 receptor agonist that augments renal plasma flow that has reduced the risk of radiocontrast dye nephropathy in some (but not all) preliminary studies. neutrophil gelatinase-associated lipocalin (ngal) is a new biomarker predictive for aki already shown to be useful for earlier diagnosis of contrast induced nephropathy. the primary objective of this study is to to test the hypothesis that fenoldopam, in addition to standard treatment, reduce the occurrence of contrast induced - acute kidney injury in patients with acute coronary syndrome (acs) undergoing urgent/emergency coronary angiography and/or percutaneous coronary intervention. patients will be randomized to standard i.v. 1 ml/kg/h saline infusion (gr. a, n= 50) or to a combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/kg/min) from 6 hours before the procedure to 12 hours after the procedure. primary end-points • incidence of contrast induced acute kidney injury secondary end-points • post-angiographic 48-h absolute increase in creatinine, absolute increase in estimated glomerular filtration rate, and neutrophil gelatinase-associated lipocalin (ngal) value

Eligibility criteria:
inclusion criteria: * indication to urgent/emergency coronary angiography * normal renal function (egfr\> 60 ml/min/1.73 m2) * moderate or high mehran's risk score for cin (\>11). * able to understand and willing to sign the informed cf exclusion criteria: • women of child bearing potential patients must demonstrate a negative pregnancy test performed within 24 hours before ct

Keywords: contrast induced acute kidney injury
disseminating public health evidence to support prevention and control of diabetes among local health departments

Conditions: Organizational Support for Evidence-based Public Health

Summary: the purpose of this study is to identify and evaluate dissemination strategies to support the uptake of evidence-based programs and policies (ebpps) for diabetes prevention and control among local-level public health practitioners. dissemination strategies such as multi-day in-person training workshops, electronic information exchange modalities, and remote technical assistance are hypothesized to associate with improved access and use of public health evidence and organizational supports for program and policy decision making based on evidence-based public health.

evidence-based public health approaches to prevent and control diabetes and other chronic diseases have been identified in recent decades, and could have a profound effect on diabetes incidence and quality and length of life of those diagnosed. however, barriers to implement approaches continue because of lack of organizational support, limited resources, competing priorities, and limited skill among the public health workforce. the purpose of this study is to determine effective ways to promote the adoption of evidence based public health practice related to diabetes and chronic disease prevention and control among local health departments (lhds). this stepped-wedge cluster randomized trial aims to evaluate active dissemination strategies on local-level public health practitioners to increase adoption and use of evidence-based programs and policies for diabetes and chronic disease prevention and control among lhds in missouri. twelve lhds will be recruited and randomly assigned to one of three groups that cross over from usual practice to receive the intervention (dissemination) strategies at 8-month intervals; the intervention duration for groups ranges from 8 to 24 months. lhd staff and the university-based study team are jointly identifying, refining and selecting dissemination strategies. intervention strategies may include multi-day in-person training workshops, electronic information exchange modalities, and remote technical assistance. evaluation methods include surveys at baseline and at each 8-month interval, abstraction of lhd chronic disease prevention program plans and progress reports, and social network analysis.

Eligibility criteria:
inclusion criteria: * local health departments (lhds, cluster) in the state of missouri and corresponding public health workforce (individuals within cluster); screenings. exclusion criteria: * lhds that have less than 5 employees working in or supporting diabetes or chronic disease control, which includes program areas of diabetes prevention and management, obesity prevention, physical activity, nutrition, cardiovascular health, and cancer

Keywords: dissemination research public health workforce evidence-based public health public health accreditation
barostim neo hypertension pivotal trial

Conditions: Uncontrolled Hypertension

Summary: the purpose of this clinical investigation (nct01679132) is to assess the long-term safety and efficacy of the barostim neo system in subjects currently participating in the barostim hypertension pivotal trial (g120137).

the barostim neo hypertension trial is a prospective, randomized, controlled trial assessing the safety and efficacy of the barostim neo system in subjects with resistant hypertension. all subjects are now in long term follow-up and are required to have at least one annual visit. parameters assessed during visits are: * office cuff blood pressure * physical assessment * subject medications * serious adverse events

Eligibility criteria:
inclusion criteria: * actively participating in the barostim hypertension pivotal trial and currently implanted with the barostim neo device with the device turned on. * have signed a revised approved informed consent form for continued participation in this study. exclusion criteria: * treating physician decision that the subject should not continue with therapy.
relationship between neurotransmitter receptor polymorphisms, plasma concentrations and clinical response to clozapine

Conditions: Schizophrenia

Summary: this is a study designed to identify genetic polymorphisms (also called allelic variants or genetic markers) that are associated with response to clozapine. this information will be used to enhance the understanding of clozapine response and side effects. dna from patients will be examined for significant associations between allelic variants in candidate genes in relation to clozapine effects on positive and negative symptoms, global response, quality of life, relapse rates and side effects.

patients age 18-65 with a dsm iv diagnosis of schizophrenia who have a history of nonresponse to conventional atypical antipsychotics and who are to be treated with clozapine by their psychiatrist, will be asked to participate at or near the time clozapine therapy is initiated. the brief psychiatric rating scale (bprs), scale for the assessment of negative symptoms (sans), and the scale for the assessment of positive symptoms (saps) will be performed on all subjects at entry into the study, at 3 weeks, 5 weeks, 8 weeks, and at 4 and 6 months. adverse effects will be monitored with the simpson-angus scale, barnes akathisia scale and the aims at each of these time points. the calgary depression scale will also be administered at each visit. a complete neurocognitive assessment battery will be completed at entry and at 6 months for those subjects willing to undergo neurocognitive testing. it is anticipated not all subjects will complete neurocognitive testing. a blood or cheek swab sample will be collected at study entry for dna analysis. plasma blood levels will be collected at weeks 3, 5, 8 and study completion for measurement of clozapine plasma concentrations. the subject's weight, bmi, smoking status and concomitant medications will be recorded at each visit.

Eligibility criteria:
inclusion criteria: * diagnosis of schizophrenia * beginning clozapine therapy * age 18-65 * must be willing to participate in interviews and provide a dna sample exclusion criteria: * no longer taking clozapine

Keywords: clozapine, schizophrenia
progressive relaxation exercise on pain, anxiety and patient satisfaction

Conditions: Effect of Progressive Relaxation Exercise

Summary: this single-center, prospective, randomized controlled trial was completed with a total of 70 patients, 35 in each of the intervention and control groups. data were collected using the patient information form, visual analogy scale and state-trait anxiety inventory. patients in the intervention group performed progressive relaxation exercise for 20 minutes before femoral sheath removal. the patients in the control group received the standard practice of the clinic.

this study aimed to determine the effect of progressive relaxation exercise (pre) applied to patients undergoing percutaneous coronary intervention (pci) on pain, anxiety and patient satisfaction related to femoral sheath removal. this single-center, prospective, randomized controlled trial was completed with a total of 70 patients, 35 in each of the intervention and control groups. data were collected using the patient information form, visual analogy scale and state-trait anxiety inventory. patients in the intervention group performed pre for 20 minutes before femoral sheath removal. the patients in the control group received the standard practice of the clinic.

Eligibility criteria:
inclusion criteria: * able to speak and understand turkish, * over 18 years of age, * intervened in the femoral region, * with only one catheter in the femoral region, * without vision and hearing problems, * undergoing angiography procedure for the first time, * with normal vital signs, * who have not been administered analgesics for any reason prior to sheath removal after the procedure, * patients who volunteered to participate in the study were included in the study. exclusion criteria: * patients with chronic pain using transdermal patches, * patients with impaired time and place orientation, * patients with psychiatric disorders.

Keywords: anxiety femoral sheath pain progressive relaxation exercise satisfaction
the contribution of lp-pla2 level to the presence of coronary plaques in patients with non alcoholic fatty liver disease

Conditions: Nonalcoholic Fatty Liver Disease; Coronary Artery Disease

Summary: the most common cause of death in patients with nafld(nonalcoholic fatty liver disease) is cad(coronary artery disease). nafld patients have 65% more mortality than general population. the aim of the investigators study is to diagnose early coronary artery disease in nafld patient by measuring of pla2. the investigators expect that pla2 will higher in patients with patients with combination of cad, unstable plaque and nafld.

background: the most common cause of death in patients with nafld(nonalcoholic fatty liver disease) is cad(coronary artery disease). nafld patients have 65% more mortality than general population. the aim of our study is to diagnose early coronary artery disease in nafld patient by measuring of pla2. methods: 60 patients with chest pain and low to intermediate risk for coronary events will undergo cardiac ct and blood test measurement of enzyme pla2, markers of inflammation: crp, mda(malondialdehide), paraoxonase, ffa(free fatty acids), tg(triglycerids) will performed. cad is defined as a stenosis of more than 50% in at least one major coronary artery, unstable plaque defined as low attenuated plaque \<30hu and fatty liver defined as difference in liver and spleen attenuation value -10hu by using ct. expected results : we expect that pla2 will higher in patients with patients with combination of cad, unstable plaque and nafld.

Eligibility criteria:
inclusion criteria: 1. patients at intermediate risk for significant cad was admitted to the hospital with the diagnosis of chest pain or undergoing elective ct coronarography due to suspection of coronary artery disease. 2. male and female 18years or older. 3. able to provide written informed consent. intermediate risk patients for having significant cad is deﬁned as: * chest pain or dyspnea in the presence of negative stress tests; * the absence of chest pain but positive stress tests; * the absence of chest pain and of positive stress tests but intermittent arrhythmias exclusion criteria: 1. acute coronary syndrome presentation: * st segment deviation on ecg and/or 2. cardiac troponin elevation. 3. chest pain in combination with positive tests for myocardial ischemia 4. hemodynamic instability on presentation. 5. inability to write inform consent. 6. age \<18 years. 7. participation in an investigational study within the previous 30days.

Keywords: nafld lp-pla2 coronary arthery disease
kd6001 in combination with anti-pd-1 antibody in patients with advanced melanoma

Conditions: Melanoma

Summary: this is a phase 1b/2, open label study to evaluate the safety, tolerability, pharmacokinetics and initial efficacy of kd6001 in combination with toripalimab in patients with advanced melanoma.


Eligibility criteria:
main inclusion criteria: 1. being voluntary to sign the informed consent form. 2. male or female, aged ≥ 18 years. 3. patients whose estimated survival time is more than 3 months. 4. eastern cooperative oncology group (ecog) performance status score 0 or 1. 5. histologically or cytologically confirmed advanced or metastatic melanoma, and the overall proportion of subjects with mucosal malignant melanoma will not exceed 22%. 6. at least one measurable lesion is used as the target lesion according to the response evaluation criteria in solid tumors version 1.1(recist v1.1). 7. the results of laboratory examination during the screening period suggest that the subjects have good organ function. 8. male subjects with reproductive ability or female subjects with the possibility of pregnancy use effective contraceptive methods. 9. good compliance and follow-up. main exclusion criteria: 1. systematic treatment with antitumor drugs within 4 weeks prior to the start of this study. 2. received immunotherapy (including pd-1/pd-l1 therapy and cell therapy) within 4 weeks prior to the start of this study. 3. prior treatment with anti-ctla-4 antibody. 4. subjects with an active, known or suspected autoimmune disease. 5. subjects with hepatitis (nonalcoholic steatohepatitis, alcoholic or drug-related, autoimmune hepatitis) and liver cirrhosis; active hepatitis b or hepatitis c. 6. subjects with an active infection requiring systemic treatment. 7. known history of testing positive for human immunodeficiency virus (hiv). 8. subjects known to have active tuberculosis (tb). 9. known to be allergic to kd6001 or toripalimab and its components.